Scholarlink

Purpose <p>Convalescent plasma (CP), obtained from individuals who have recovered from COVID-19, has been widely explored as a potential therapeutic option, particularly in the absence of vaccines and monoclonal antibody treatments. This study aimed to evaluate the effectiveness of CP therapy in improving survival among non-immunized COVID-19 patients hospitalized in Brazil.</p> Methods <p>This retrospective unicentric cohort study was conducted at a private hospital in Campo Largo, Paraná, Brazil, from July 2020 to February 2021. A total of 245 hospitalized COVID-19 patients were included, confirmed by RT-qPCR or antigen testing. Patients were divided into two groups: those receiving CP alongside standard treatment (n=100) and those receiving standard treatment alone (n=145). Survival outcomes were assessed using Kaplan-Meier analysis and Cox regression, while inflammatory responses were evaluated through C-reactive protein (CRP) measurements.</p> Results <p>Patients treated with CP had a significantly higher survival rate (91%) compared to the control group (82.8%) (P=0.0363). The survival benefit persisted throughout the follow-up period, with a 2.25-fold lower risk of death in the CP group after adjusting for age (P=0.0480). However, no significant differences in CRP levels were observed between groups at discharge, suggesting that CP's benefits may be mediated through immune modulation rather than direct anti-inflammatory effects.</p> Conclusions <p>Our findings indicate that CP therapy significantly improves survival in non-immunized COVID-19 patients, reinforcing its potential role in settings with limited access to advanced treatments. Future studies should explore CP’s mechanisms of action and its integration into broader therapeutic strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy of convalescent plasma therapy in improving survival in non-immunized COVID-19 patients

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月24日

查看全文
  • Tania Portella Costa,
  • Dayanne Mozaner Bordin,
  • Mateus Nóbrega Aoki,
  • Lucas Blanes

摘要

Purpose

Convalescent plasma (CP), obtained from individuals who have recovered from COVID-19, has been widely explored as a potential therapeutic option, particularly in the absence of vaccines and monoclonal antibody treatments. This study aimed to evaluate the effectiveness of CP therapy in improving survival among non-immunized COVID-19 patients hospitalized in Brazil.

Methods

This retrospective unicentric cohort study was conducted at a private hospital in Campo Largo, Paraná, Brazil, from July 2020 to February 2021. A total of 245 hospitalized COVID-19 patients were included, confirmed by RT-qPCR or antigen testing. Patients were divided into two groups: those receiving CP alongside standard treatment (n=100) and those receiving standard treatment alone (n=145). Survival outcomes were assessed using Kaplan-Meier analysis and Cox regression, while inflammatory responses were evaluated through C-reactive protein (CRP) measurements.

Results

Patients treated with CP had a significantly higher survival rate (91%) compared to the control group (82.8%) (P=0.0363). The survival benefit persisted throughout the follow-up period, with a 2.25-fold lower risk of death in the CP group after adjusting for age (P=0.0480). However, no significant differences in CRP levels were observed between groups at discharge, suggesting that CP's benefits may be mediated through immune modulation rather than direct anti-inflammatory effects.

Conclusions

Our findings indicate that CP therapy significantly improves survival in non-immunized COVID-19 patients, reinforcing its potential role in settings with limited access to advanced treatments. Future studies should explore CP’s mechanisms of action and its integration into broader therapeutic strategies.